Veru reports fiscal 2025 results, plans obesity drug trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Veru reports fiscal 2025 results, plans obesity drug trial

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

December 17, 2025 6:30 AM EST

-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA --

-- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements --

-- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 --

-- Post fiscal year end, company completed public offering for net proceeds of approximately $23.4 million... More